NPORT-EX 2 edgar.htm EDGAR HTML
Schedule of Investments(a)
Invesco Nasdaq Biotechnology ETF (IBBQ)
November 30, 2024
(Unaudited)
 
 
Shares
Value
Common Stocks & Other Equity Interests-99.92%
Biotechnology-80.62%
4D Molecular Therapeutics, Inc.(b)(c)
 
2,171
$17,021
89bio, Inc.(b)(c)
 
4,436
39,880
AC Immune S.A. (Switzerland)(b)
 
4,135
14,059
Acadia Pharmaceuticals, Inc.(b)(c)
 
6,944
113,326
ACELYRIN, Inc.(b)(c)
 
4,189
19,060
ADMA Biologics, Inc.(b)
 
9,761
196,294
Agios Pharmaceuticals, Inc.(b)(c)
 
2,374
140,992
Akero Therapeutics, Inc.(b)(c)
 
2,900
93,090
Alector, Inc.(b)
 
4,076
10,557
Alkermes PLC(b)
 
6,899
200,209
Allogene Therapeutics, Inc.(b)(c)
 
8,751
21,702
Alnylam Pharmaceuticals, Inc.(b)
 
5,380
1,361,517
ALX Oncology Holdings, Inc.(b)(c)
 
2,197
3,252
Amarin Corp. PLC, ADR (Ireland)(b)
 
16,769
8,497
Amgen, Inc.
 
10,370
2,933,362
Amicus Therapeutics, Inc.(b)
 
12,421
123,962
AnaptysBio, Inc.(b)(c)
 
1,262
31,500
Anavex Life Sciences Corp.(b)(c)
 
3,551
33,592
Apellis Pharmaceuticals, Inc.(b)
 
5,105
173,213
Apogee Therapeutics, Inc.(b)(c)
 
1,892
85,424
Arbutus Biopharma Corp.(b)
 
7,915
27,386
Arcellx, Inc.(b)(c)
 
2,258
198,862
Arcturus Therapeutics Holdings, Inc.(b)(c)
 
1,125
20,632
Arcutis Biotherapeutics, Inc.(b)(c)
 
4,904
63,948
Ardelyx, Inc.(b)(c)
 
9,869
55,957
argenx SE, ADR (Netherlands)(b)
 
1,353
834,192
Arrowhead Pharmaceuticals, Inc.(b)(c)
 
5,200
135,356
ARS Pharmaceuticals, Inc.(b)(c)
 
4,062
58,940
Ascendis Pharma A/S, ADR (Denmark)(b)
 
2,433
331,083
Aurinia Pharmaceuticals, Inc. (Canada)(b)
 
5,994
53,107
Autolus Therapeutics PLC, ADR (United
Kingdom)(b)
 
8,358
27,749
Avidity Biosciences, Inc.(b)(c)
 
4,912
211,363
Beam Therapeutics, Inc.(b)(c)
 
3,463
94,782
BeiGene Ltd., ADR (China)(b)(c)
 
1,867
401,405
Bicycle Therapeutics PLC, ADR (United
Kingdom)(b)(c)
 
1,559
31,804
BioCryst Pharmaceuticals, Inc.(b)(c)
 
8,668
65,010
Biogen, Inc.(b)
 
6,119
982,895
BioMarin Pharmaceutical, Inc.(b)(c)
 
7,975
526,589
Biomea Fusion, Inc.(b)(c)
 
1,526
11,048
BioNTech SE, ADR (Germany)(b)(c)
 
4,103
485,754
bluebird bio, Inc.(b)(c)
 
7,974
3,229
Blueprint Medicines Corp.(b)(c)
 
2,654
255,792
BridgeBio Pharma, Inc.(b)
 
7,887
213,659
Cabaletta Bio, Inc.(b)(c)
 
2,055
7,850
Caribou Biosciences, Inc.(b)(c)
 
3,778
8,274
Cartesian Therapeutics, Inc., Rts., expiring
12/02/2024(b)(d)
 
2,633
474
Centessa Pharmaceuticals PLC, ADR(b)(c)
 
2,966
53,121
Cogent Biosciences, Inc.(b)
 
4,587
43,622
Coherus BioSciences, Inc.(b)(c)
 
4,821
5,882
Crinetics Pharmaceuticals, Inc.(b)
 
3,354
191,849
CRISPR Therapeutics AG (Switzerland)(b)(c)
 
3,565
182,421
Cullinan Therapeutics, Inc.(b)(c)
 
2,434
32,737
CureVac N.V. (Germany)(b)(c)
 
9,396
26,967
Cytokinetics, Inc.(b)(c)
 
4,932
255,774
Day One Biopharmaceuticals, Inc.(b)(c)
 
4,190
58,367
Denali Therapeutics, Inc.(b)(c)
 
6,000
150,000
Disc Medicine, Inc.(b)
 
1,245
78,995
Dynavax Technologies Corp.(b)
 
5,490
70,601
 
Shares
Value
Biotechnology-(continued)
Dyne Therapeutics, Inc.(b)(c)
 
4,211
$128,899
Editas Medicine, Inc.(b)(c)
 
3,465
7,762
Erasca, Inc.(b)(c)
 
11,838
33,857
Exelixis, Inc.(b)(c)
 
11,960
436,062
Galapagos N.V., ADR (Belgium)(b)(c)
 
853
23,577
Genmab A/S, ADR (Denmark)(b)
 
1,758
37,797
Geron Corp.(b)
 
25,260
104,071
Gilead Sciences, Inc.
 
43,783
4,053,430
GRAIL, Inc.(b)(c)
 
1,294
22,645
Grifols S.A., ADR (Spain)(b)(c)
 
5,113
35,740
Halozyme Therapeutics, Inc.(b)(c)
 
5,307
255,797
Humacyte, Inc.(b)(c)
 
4,995
22,577
Ideaya Biosciences, Inc.(b)
 
3,539
96,827
ImmunityBio, Inc.(b)(c)
 
29,183
147,082
Immunocore Holdings PLC, ADR (United
Kingdom)(b)(c)
 
1,616
52,908
Immunovant, Inc.(b)(c)
 
6,139
173,120
Incyte Corp.(b)
 
8,077
602,463
Insmed, Inc.(b)(c)
 
7,206
541,603
Intellia Therapeutics, Inc.(b)(c)
 
4,255
66,463
Ionis Pharmaceuticals, Inc.(b)(c)
 
6,133
219,132
Iovance Biotherapeutics, Inc.(b)(c)
 
12,719
118,541
Ironwood Pharmaceuticals, Inc.(b)(c)
 
6,696
23,570
iTeos Therapeutics, Inc.(b)
 
1,537
13,141
Janux Therapeutics, Inc.(b)(c)
 
2,178
98,467
KalVista Pharmaceuticals, Inc.(b)(c)
 
1,801
18,118
Keros Therapeutics, Inc.(b)
 
1,574
90,883
Kiniksa Pharmaceuticals International PLC(b)(c)
 
1,709
37,735
Krystal Biotech, Inc.(b)
 
1,208
238,483
Kura Oncology, Inc.(b)
 
3,208
35,416
Kymera Therapeutics, Inc.(b)(c)
 
2,700
126,495
Legend Biotech Corp., ADR(b)(c)
 
3,415
143,669
Lexicon Pharmaceuticals, Inc.(b)(c)
 
15,153
12,178
Lyell Immunopharma, Inc.(b)(c)
 
10,733
10,144
MacroGenics, Inc.(b)(c)
 
2,631
9,445
Madrigal Pharmaceuticals, Inc.(b)(c)
 
907
297,668
MannKind Corp.(b)(c)
 
11,519
78,099
MeiraGTx Holdings PLC(b)
 
3,236
21,908
Merus N.V. (Netherlands)(b)
 
2,855
128,018
Mineralys Therapeutics, Inc.(b)(c)
 
2,088
26,664
Mirum Pharmaceuticals, Inc.(b)(c)
 
1,993
92,116
Moderna, Inc.(b)
 
16,131
694,601
Myriad Genetics, Inc.(b)
 
3,795
61,745
Neurocrine Biosciences, Inc.(b)
 
4,232
536,406
Novavax, Inc.(b)(c)
 
6,709
58,502
Nurix Therapeutics, Inc.(b)(c)
 
2,694
59,564
Nuvalent, Inc., Class A(b)(c)
 
2,486
240,346
Olema Pharmaceuticals, Inc.(b)(c)
 
2,408
24,369
OmniAb Operations, Inc., Rts., expiring
11/02/2027(b)(c)(d)
 
125
0
OmniAb Operations, Inc., Rts., expiring
11/02/2027(b)(d)
 
125
0
OnKure Therapeutics, Inc.(b)
 
144
2,220
ORIC Pharmaceuticals, Inc.(b)(c)
 
2,961
29,314
Ovid therapeutics, Inc.(b)
 
2,977
3,394
Precigen, Inc.(b)(c)
 
12,051
11,233
Prime Medicine, Inc.(b)(c)
 
5,020
16,516
Protagonist Therapeutics, Inc.(b)(c)
 
2,469
108,142
Prothena Corp. PLC (Ireland)(b)(c)
 
2,258
36,602
PTC Therapeutics, Inc.(b)(c)
 
3,219
141,250
RAPT Therapeutics, Inc.(b)
 
1,457
1,836
Recursion Pharmaceuticals, Inc., Class A(b)(c)
 
13,137
92,879
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
November 30, 2024
(Unaudited)
 
Shares
Value
Biotechnology-(continued)
Regeneron Pharmaceuticals, Inc.(b)
 
2,913
$2,185,391
REGENXBIO, Inc.(b)(c)
 
2,077
20,604
Relay Therapeutics, Inc.(b)
 
5,615
26,390
Replimune Group, Inc.(b)(c)
 
2,859
40,255
REVOLUTION Medicines, Inc.(b)(c)
 
7,007
405,355
Rhythm Pharmaceuticals, Inc.(b)(c)
 
2,552
158,326
Rocket Pharmaceuticals, Inc.(b)(c)
 
3,822
54,999
Roivant Sciences Ltd.(b)(c)
 
30,981
393,768
Sage Therapeutics, Inc.(b)(c)
 
2,549
13,943
Sana Biotechnology, Inc.(b)(c)
 
9,327
25,929
Sarepta Therapeutics, Inc.(b)(c)
 
4,004
533,893
Savara, Inc.(b)
 
6,897
23,174
Scholar Rock Holding Corp.(b)(c)
 
3,354
133,825
SpringWorks Therapeutics, Inc.(b)(c)
 
3,120
129,418
Summit Therapeutics, Inc.(b)(c)
 
30,344
560,150
Syndax Pharmaceuticals, Inc.(b)(c)
 
3,562
59,557
Tango Therapeutics, Inc.(b)(c)
 
4,481
17,655
Taysha Gene Therapies, Inc.(b)(c)
 
8,596
27,851
Tourmaline Bio, Inc.(b)(c)
 
1,073
27,941
Travere Therapeutics, Inc.(b)(c)
 
3,202
60,230
Twist Bioscience Corp.(b)
 
2,457
120,835
Ultragenyx Pharmaceutical, Inc.(b)
 
3,865
184,090
uniQure N.V. (Netherlands)(b)(c)
 
2,050
12,238
United Therapeutics Corp.(b)
 
1,873
693,928
UroGen Pharma Ltd.(b)(c)
 
1,765
22,415
Vanda Pharmaceuticals, Inc.(b)(c)
 
2,446
12,597
Vaxcyte, Inc.(b)(c)
 
4,681
441,606
Vera Therapeutics, Inc.(b)(c)
 
2,297
114,276
Veracyte, Inc.(b)(c)
 
3,214
138,041
Vericel Corp.(b)(c)
 
2,062
119,885
Vertex Pharmaceuticals, Inc.(b)
 
6,970
3,262,866
Verve Therapeutics, Inc.(b)(c)
 
3,545
19,887
Vir Biotechnology, Inc.(b)
 
5,718
45,515
Voyager Therapeutics, Inc.(b)(c)
 
2,286
15,682
Xencor, Inc.(b)(c)
 
2,598
66,509
Xenon Pharmaceuticals, Inc. (Canada)(b)
 
3,175
135,350
Y-mAbs Therapeutics, Inc.(b)
 
1,876
22,362
Zai Lab Ltd., ADR (China)(b)(c)
 
2,087
60,210
Zentalis Pharmaceuticals, Inc.(b)
 
2,982
10,765
Zymeworks, Inc.(b)(c)
 
2,980
41,988
 
 
33,119,173
Health Care Equipment & Supplies-0.22%
Novocure Ltd.(b)(c)
 
4,541
91,001
Health Care Providers & Services-0.54%
23andMe Holding Co., Class A(b)
 
711
2,524
Castle Biosciences, Inc.(b)(c)
 
1,171
35,458
Guardant Health, Inc.(b)
 
5,152
183,463
 
 
221,445
Life Sciences Tools & Services-4.04%
AbCellera Biologics, Inc. (Canada)(b)
 
12,350
37,174
Adaptive Biotechnologies Corp.(b)
 
6,180
36,709
Fortrea Holdings, Inc.(b)(c)
 
3,750
78,937
Illumina, Inc.(b)(c)
 
6,680
962,922
Maravai LifeSciences Holdings, Inc., Class A(b)
 
5,940
33,680
MaxCyte, Inc.(b)(c)
 
4,405
15,638
Medpace Holdings, Inc.(b)(c)
 
1,297
441,797
Nautilus Biotechnology, Inc.(b)
 
5,260
11,782
OmniAb, Inc.(b)(c)
 
4,951
19,358
Pacific Biosciences of California, Inc.(b)(c)
 
11,427
21,826
 
 
1,659,823
 
Shares
Value
Pharmaceuticals-14.50%
Aclaris Therapeutics, Inc.(b)
 
2,991
$12,173
Amphastar Pharmaceuticals, Inc.(b)
 
2,049
92,594
Amylyx Pharmaceuticals, Inc.(b)(c)
 
2,850
15,789
ANI Pharmaceuticals, Inc.(b)
 
881
50,420
Arvinas, Inc.(b)(c)
 
2,871
76,713
AstraZeneca PLC, ADR (United Kingdom)
 
24,426
1,651,686
ATAI Life Sciences N.V. (Germany)(b)(c)
 
7,035
12,522
Atea Pharmaceuticals, Inc.(b)(c)
 
3,537
12,097
Avadel Pharmaceuticals PLC(b)(c)
 
4,037
44,649
Axsome Therapeutics, Inc.(b)(c)
 
2,004
196,833
Collegium Pharmaceutical, Inc.(b)(c)
 
1,357
41,389
Edgewise Therapeutics, Inc.(b)
 
3,925
129,525
Enliven Therapeutics, Inc.(b)(c)
 
1,975
48,150
Evolus, Inc.(b)
 
2,645
36,210
EyePoint Pharmaceuticals, Inc.(b)(c)
 
2,249
19,904
Fulcrum Therapeutics, Inc.(b)(c)
 
2,619
10,083
Harmony Biosciences Holdings, Inc.(b)(c)
 
2,372
82,237
Harrow, Inc.(b)
 
1,479
61,985
Hutchmed (China) Ltd., ADR (China)(b)(c)
 
1,293
21,916
Innoviva, Inc.(b)(c)
 
2,625
49,849
Intra-Cellular Therapies, Inc.(b)
 
4,427
379,173
Jazz Pharmaceuticals PLC(b)
 
2,595
315,526
Ligand Pharmaceuticals, Inc.(b)(c)
 
759
92,196
Marinus Pharmaceuticals, Inc.(b)(c)
 
2,307
749
Ocular Therapeutix, Inc.(b)(c)
 
6,534
64,621
Pacira BioSciences, Inc.(b)(c)
 
1,934
32,704
Phathom Pharmaceuticals, Inc.(b)(c)
 
2,858
25,350
Phibro Animal Health Corp., Class A
 
856
20,005
Pliant Therapeutics, Inc.(b)(c)
 
2,539
35,038
Revance Therapeutics, Inc.(b)(c)
 
4,395
15,866
Royalty Pharma PLC, Class A
 
18,773
500,488
Sanofi S.A., ADR
 
12,244
593,712
SIGA Technologies, Inc.(c)
 
2,992
21,782
Structure Therapeutics, Inc., ADR(b)(c)
 
2,494
82,676
Supernus Pharmaceuticals, Inc.(b)
 
2,308
84,404
Tarsus Pharmaceuticals, Inc.(b)(c)
 
1,594
83,605
Terns Pharmaceuticals, Inc.(b)
 
2,955
18,439
Theravance Biopharma, Inc.(b)
 
2,058
19,037
Third Harmonic Bio, Inc.(b)(c)
 
1,727
22,037
Ventyx Biosciences, Inc.(b)
 
2,966
7,949
Verona Pharma PLC, ADR (United
Kingdom)(b)(c)
 
3,022
119,762
Viatris, Inc.
 
49,991
654,382
WaVe Life Sciences Ltd.(b)(c)
 
5,235
79,048
Xeris Biopharma Holdings, Inc.(b)
 
6,237
20,457
 
 
5,955,730
Total Common Stocks & Other Equity Interests
(Cost $43,041,158)
41,047,172
 
Money Market Funds-0.01%
Invesco Government & Agency Portfolio,
Institutional Class, 4.57%(e)(f)
(Cost $4,110)
 
4,110
4,110
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-99.93%
(Cost $43,045,268)
41,051,282
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Biotechnology ETF (IBBQ)—(continued)
November 30, 2024
(Unaudited)
 
Shares
Value
Investments Purchased with Cash Collateral
from Securities on Loan
Money Market Funds-28.80%
Invesco Private Government Fund,
4.63%(e)(f)(g)
 
3,314,931
$3,314,931
Invesco Private Prime Fund, 4.71%(e)(f)(g)
 
8,514,710
8,517,264
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $11,832,499)
11,832,195
TOTAL INVESTMENTS IN SECURITIES-128.73%
(Cost $54,877,767)
52,883,477
OTHER ASSETS LESS LIABILITIES-(28.73)%
(11,801,421
)
NET ASSETS-100.00%
$41,082,056
 
 
Investment Abbreviations:
ADR
-American Depositary Receipt
Rts.
-Rights
 
Notes to Schedule of Investments:
(a)
Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
(b)
Non-income producing security.
(c)
All or a portion of this security was out on loan at November 30, 2024.
(d)
Security valued using significant unobservable inputs (Level 3). See Note 1.
(e)
Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the three months ended November 30, 2024.
 
 
Value
August 31, 2024
Purchases
at Cost
Proceeds
from Sales
Change in
Unrealized
Appreciation
(Depreciation)
Realized
Gain
Value
November 30, 2024
Dividend
Income
Investments in Affiliated
Money Market Funds:
Invesco Government & Agency
Portfolio, Institutional Class
$-
$125,506
$(121,396
)
$-
$-
$4,110
$170
Investments Purchased with
Cash Collateral from
Securities on Loan:
Invesco Private Government
Fund
2,870,230
5,760,345
(5,315,644
)
-
-
3,314,931
35,609
*
Invesco Private Prime Fund
7,371,186
10,130,689
(8,983,931
)
(788
)
108
8,517,264
94,253
*
Total
$10,241,416
$16,016,540
$(14,420,971
)
$(788
)
$108
$11,836,305
$130,032
 
*
Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from
borrowers, if any.
 
(f)
The rate shown is the 7-day SEC standardized yield as of November 30, 2024.
(g)
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.  
The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.
See accompanying notes which are an integral part of this schedule.
Schedule of Investments(a)
Invesco Nasdaq Free Cash Flow Achievers ETF (QOWZ)
November 30, 2024
(Unaudited)
 
 
Shares
Value
Common Stocks & Other Equity Interests-99.92%
Automobiles-0.68%
Thor Industries, Inc.(b)
 
673
$75,107
Building Products-1.19%
Owens Corning
 
638
131,185
Commercial Services & Supplies-5.39%
Cintas Corp.
 
1,102
248,820
Republic Services, Inc.
 
972
212,188
Rollins, Inc.
 
2,654
133,576
 
 
594,584
Consumer Finance-2.25%
Capital One Financial Corp.
 
1,292
248,077
Distributors-1.01%
Pool Corp.
 
295
111,241
Electrical Equipment-0.94%
Acuity Brands, Inc.
 
324
103,904
Electronic Equipment, Instruments & Components-4.06%
Amphenol Corp., Class A
 
3,286
238,728
Littelfuse, Inc.
 
285
70,301
Teledyne Technologies, Inc.(c)
 
286
138,784
 
 
447,813
Entertainment-1.46%
Warner Bros. Discovery, Inc.(c)
 
15,389
161,277
Financial Services-4.54%
Mastercard, Inc., Class A
 
940
500,964
Food Products-1.09%
McCormick & Co., Inc.
 
1,538
120,595
Health Care Providers & Services-4.64%
UnitedHealth Group, Inc.
 
840
512,568
Health Care Technology-0.24%
Simulations Plus, Inc.(b)
 
833
26,464
Hotels, Restaurants & Leisure-2.27%
Marriott International, Inc., Class A
 
866
250,352
Household Durables-1.91%
Cavco Industries, Inc.(b)(c)
 
141
72,544
NVR, Inc.(c)
 
15
138,534
 
 
211,078
Interactive Media & Services-6.76%
Meta Platforms, Inc., Class A
 
1,299
746,042
IT Services-1.08%
VeriSign, Inc.(c)
 
637
119,234
Life Sciences Tools & Services-5.08%
Mettler-Toledo International, Inc.(c)
 
102
127,622
Thermo Fisher Scientific, Inc.
 
564
298,711
West Pharmaceutical Services, Inc.
 
414
134,832
 
 
561,165
Machinery-0.70%
Watts Water Technologies, Inc., Class A
 
358
77,253
Media-0.34%
TechTarget, Inc.(c)
 
1,157
37,151
Metals & Mining-0.28%
Radius Recycling, Inc., Class A
 
1,586
31,434
Oil, Gas & Consumable Fuels-2.10%
Kinder Morgan, Inc.
 
8,218
232,323
 
Shares
Value
Professional Services-4.46%
Automatic Data Processing, Inc.
 
923
$283,296
DLH Holdings Corp.(c)
 
1,444
12,462
Paychex, Inc.
 
1,343
196,441
 
 
492,199
Semiconductors & Semiconductor Equipment-19.60%
Broadcom, Inc.
 
3,499
567,118
KLA Corp.
 
308
199,285
Microchip Technology, Inc.
 
2,084
142,066
NVIDIA Corp.
 
8,451
1,168,351
Rambus, Inc.(c)
 
1,503
86,889
 
 
2,163,709
Software-25.24%
Adobe, Inc.(c)
 
625
322,456
Cadence Design Systems, Inc.(c)
 
790
242,380
Fair Isaac Corp.(c)
 
97
230,378
Fortinet, Inc.(c)
 
2,518
239,336
Intuit, Inc.
 
488
313,164
Manhattan Associates, Inc.(c)
 
426
121,598
Progress Software Corp.
 
875
59,859
PTC, Inc.(c)
 
706
141,242
Qualys, Inc.(c)
 
527
80,947
Roper Technologies, Inc.
 
351
198,821
Salesforce, Inc.
 
1,391
459,015
ServiceNow, Inc.(c)
 
360
377,798
 
 
2,786,994
Trading Companies & Distributors-2.61%
Beacon Roofing Supply, Inc.(c)
 
790
89,286
Fastenal Co.
 
2,385
199,290
 
 
288,576
Total Common Stocks & Other Equity Interests
(Cost $9,482,023)
11,031,289
 
Money Market Funds-0.08%
Invesco Government & Agency Portfolio,
Institutional Class, 4.57%(d)(e)
(Cost $9,419)
 
9,419
9,419
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral from
securities on loan)-100.00%
(Cost $9,491,442)
11,040,708
Investments Purchased with Cash Collateral
from Securities on Loan
Money Market Funds-1.35%
Invesco Private Government Fund, 4.63%(d)(e)(f)
 
41,689
41,689
Invesco Private Prime Fund, 4.71%(d)(e)(f)
 
107,035
107,067
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $148,756)
148,756
TOTAL INVESTMENTS IN SECURITIES-101.35%
(Cost $9,640,198)
11,189,464
OTHER ASSETS LESS LIABILITIES-(1.35)%
(148,963
)
NET ASSETS-100.00%
$11,040,501
 
See accompanying notes which are an integral part of this schedule.
Invesco Nasdaq Free Cash Flow Achievers ETF (QOWZ)—(continued)
November 30, 2024
(Unaudited)
Notes to Schedule of Investments:
(a)
Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
(b)
All or a portion of this security was out on loan at November 30, 2024.
(c)
Non-income producing security.
(d)
Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the three months ended November 30, 2024.
 
 
Value
August 31, 2024
Purchases
at Cost
Proceeds
from Sales
Change in
Unrealized
Appreciation
(Depreciation)
Realized
Gain
(Loss)
Value
November 30, 2024
Dividend
Income
Investments in Affiliated Money
Market Funds:
Invesco Government & Agency
Portfolio, Institutional Class
$6,725
$55,633
$(52,939
)
$-
$-
$9,419
$100
Investments Purchased with
Cash Collateral from Securities
on Loan:
Invesco Private Government Fund
19,183
312,433
(289,927
)
-
-
41,689
303
*
Invesco Private Prime Fund
50,888
779,724
(723,533
)
(3
)
(9
)
107,067
806
*
Total
$76,796
$1,147,790
$(1,066,399
)
$(3
)
$(9
)
$158,175
$1,209
 
*
Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from
borrowers, if any.
 
(e)
The rate shown is the 7-day SEC standardized yield as of November 30, 2024.
(f)
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.  
The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.
See accompanying notes which are an integral part of this schedule.
Schedule of Investments(a)
Invesco PHLX Semiconductor ETF (SOXQ)
November 30, 2024
(Unaudited)
 
 
Shares
Value
Common Stocks & Other Equity Interests-99.95%
Electronic Equipment, Instruments & Components-1.24%
Coherent Corp.(b)
 
59,313
$5,940,790
Semiconductors & Semiconductor Equipment-98.71%
Advanced Micro Devices, Inc.(b)
 
271,287
37,213,794
Amkor Technology, Inc.
 
95,329
2,520,499
Analog Devices, Inc.
 
85,806
18,709,998
Applied Materials, Inc.
 
102,156
17,847,675
ARM Holdings PLC, ADR(b)(c)
 
48,415
6,501,650
ASML Holding N.V., New York Shares
(Netherlands)
 
22,294
15,307,283
Broadcom, Inc.
 
309,407
50,148,687
Cirrus Logic, Inc.(b)
 
20,664
2,158,355
Entegris, Inc.(c)
 
58,412
6,170,060
GLOBALFOUNDRIES, Inc.(b)(c)
 
213,400
9,229,550
Intel Corp.
 
914,296
21,988,819
KLA Corp.
 
24,593
15,912,409
Lam Research Corp.
 
245,442
18,133,255
Lattice Semiconductor Corp.(b)
 
53,305
3,025,059
MACOM Technology Solutions Holdings,
Inc.(b)
 
27,931
3,709,795
Marvell Technology, Inc.
 
264,309
24,498,801
Microchip Technology, Inc.
 
207,575
14,150,388
Micron Technology, Inc.
 
209,384
20,509,163
Monolithic Power Systems, Inc.
 
18,861
10,706,258
NVIDIA Corp.
 
506,435
70,014,639
NXP Semiconductors N.V. (China)
 
78,606
18,029,858
ON Semiconductor Corp.(b)
 
165,731
11,786,789
Onto Innovation, Inc.(b)
 
19,108
3,137,151
Qorvo, Inc.(b)
 
36,701
2,534,204
QUALCOMM, Inc.
 
114,950
18,223,023
Skyworks Solutions, Inc.
 
61,796
5,412,712
Taiwan Semiconductor Manufacturing Co.
Ltd., ADR (Taiwan)
 
117,361
21,671,882
 
Shares
Value
Semiconductors & Semiconductor Equipment-(continued)
Teradyne, Inc.
 
63,134
$6,944,740
Texas Instruments, Inc.
 
94,016
18,900,036
 
 
475,096,532
Total Common Stocks & Other Equity Interests
(Cost $461,080,747)
481,037,322
 
Money Market Funds-0.03%
Invesco Government & Agency Portfolio,
Institutional Class, 4.57%(d)(e)
(Cost $153,892)
 
153,892
153,892
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-99.98%
(Cost $461,234,639)
481,191,214
Investments Purchased with Cash Collateral
from Securities on Loan
Money Market Funds-3.68%
Invesco Private Government Fund,
4.63%(d)(e)(f)
 
4,753,033
4,753,033
Invesco Private Prime Fund, 4.71%(d)(e)(f)
 
12,963,993
12,967,882
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $17,720,915)
17,720,915
TOTAL INVESTMENTS IN SECURITIES-103.66%
(Cost $478,955,554)
498,912,129
OTHER ASSETS LESS LIABILITIES-(3.66)%
(17,611,959
)
NET ASSETS-100.00%
$481,300,170
 
 
Investment Abbreviations:
ADR
-American Depositary Receipt
 
Notes to Schedule of Investments:
(a)
Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
(b)
Non-income producing security.
(c)
All or a portion of this security was out on loan at November 30, 2024.
(d)
Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the three months ended November 30, 2024.
 
 
Value
August 31, 2024
Purchases
at Cost
Proceeds
from Sales
Change in
Unrealized
Appreciation
(Depreciation)
Realized
Gain
(Loss)
Value
November 30, 2024
Dividend
Income
Investments in Affiliated
Money Market Funds:
Invesco Government & Agency
Portfolio, Institutional Class
$205,395
$949,614
$(1,001,117
)
$-
$-
$153,892
$2,017
See accompanying notes which are an integral part of this schedule.
Invesco PHLX Semiconductor ETF (SOXQ)—(continued)
November 30, 2024
(Unaudited)
 
Value
August 31, 2024
Purchases
at Cost
Proceeds
from Sales
Change in
Unrealized
Appreciation
(Depreciation)
Realized
Gain
(Loss)
Value
November 30, 2024
Dividend
Income
Investments Purchased with
Cash Collateral from
Securities on Loan:
Invesco Private Government
Fund
$7,025,751
$17,635,833
$(19,908,551
)
$-
$-
$4,753,033
$56,711
*
Invesco Private Prime Fund
10,957,299
25,727,358
(23,715,348
)
(186
)
(1,241
)
12,967,882
148,793
*
Total
$18,188,445
$44,312,805
$(44,625,016
)
$(186
)
$(1,241
)
$17,874,807
$207,521
 
*
Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from
borrowers, if any.
 
(e)
The rate shown is the 7-day SEC standardized yield as of November 30, 2024.
(f)
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.  
The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.
See accompanying notes which are an integral part of this schedule.
Schedule of Investments(a)
Invesco Solar ETF (TAN)
November 30, 2024
(Unaudited)
 
 
Shares
Value
Common Stocks & Other Equity Interests-100.04%
Construction & Engineering-1.10%
West Holdings Corp. (Japan)(b)
 
808,688
$10,139,225
Electrical Equipment-17.85%
Array Technologies, Inc.(b)(c)
 
3,787,271
25,412,588
Nextracker, Inc., Class A(b)(c)
 
2,003,770
76,463,863
Shoals Technologies Group, Inc.,
Class A(b)(c)
 
3,956,467
20,652,758
Sunrun, Inc.(b)(c)
 
3,686,784
42,508,620
 
 
165,037,829
Financial Services-3.89%
HA Sustainable Infrastructure Capital,
Inc.(b)
 
1,146,764
35,962,519
Independent Power and Renewable Electricity Producers-27.68%
Altus Power, Inc.(b)(c)
 
2,645,256
11,427,506
Atlantica Sustainable Infrastructure PLC
(Spain)
 
987,895
21,674,416
Clearway Energy, Inc., Class C
 
1,025,296
30,235,979
Doral Group Renewable Energy Resources
Ltd. (Israel)(b)(c)
 
3,391,371
11,753,407
Energix-Renewable Energies Ltd.
(Israel)(b)
 
4,505,145
14,981,421
Enlight Renewable Energy Ltd.
(Israel)(b)(c)
 
1,585,567
26,454,834
Grenergy Renovables S.A. (Spain)(b)(c)
 
448,171
13,632,722
Neoen S.A. (France)(d)
 
852,720
35,611,433
OY Nofar Energy Ltd. (Israel)(b)(c)
 
627,567
15,464,560
ReNew Energy Global PLC, Class A
(India)(b)(c)
 
1,643,222
9,908,629
RENOVA, Inc. (Japan)(b)(c)
 
1,159,393
6,137,214
Scatec ASA (South Africa)(c)(d)
 
1,974,497
14,396,025
Solaria Energia y Medio Ambiente S.A.
(Spain)(b)(c)
 
2,028,997
19,415,829
Sunnova Energy International, Inc.(b)(c)
 
2,606,318
14,439,002
Xinyi Energy Holdings Ltd. (China)(b)
 
101,246,434
10,408,871
 
 
255,941,848
Semiconductors & Semiconductor Equipment-49.52%
Canadian Solar, Inc. (Canada)(b)(c)
 
1,442,868
17,905,992
Daqo New Energy Corp., ADR (China)(b)(c)
 
1,319,432
26,428,223
Enphase Energy, Inc.(b)(c)
 
967,195
69,009,363
First Solar, Inc.(c)
 
464,637
92,588,215
Flat Glass Group Co. Ltd., H Shares
(China)(b)
 
14,110,195
25,132,178
 
Shares
Value
Semiconductors & Semiconductor Equipment-(continued)
GCL Technology Holdings Ltd.
(China)(b)(c)
 
404,956,484
$75,458,861
JinkoSolar Holding Co. Ltd., ADR
(China)(b)
 
1,197,806
26,579,315
Motech Industries, Inc. (Taiwan)
 
16,488,000
12,080,608
SMA Solar Technology AG (Germany)(b)
 
679,401
9,802,192
SolarEdge Technologies, Inc.(b)(c)
 
1,680,898
26,558,189
TSEC Corp. (Taiwan)
 
20,494,000
12,429,018
United Renewable Energy Co. Ltd.
(Taiwan)(c)
 
47,948,458
15,868,175
Xinyi Solar Holdings Ltd. (China)(b)
 
108,447,446
47,941,505
 
 
457,781,834
Total Common Stocks & Other Equity Interests
(Cost $1,632,986,841)
924,863,255
 
Money Market Funds-1.05%
Invesco Government & Agency Portfolio,
Institutional Class, 4.57%(e)(f)
(Cost $9,706,932)
 
9,706,932
9,706,932
TOTAL INVESTMENTS IN SECURITIES
(excluding investments purchased with cash collateral
from securities on loan)-101.09%
(Cost $1,642,693,773)
934,570,187
Investments Purchased with Cash Collateral
from Securities on Loan
Money Market Funds-31.78%
Invesco Private Government Fund,
4.63%(e)(f)(g)
 
82,302,590
82,302,590
Invesco Private Prime Fund, 4.71%(e)(f)(g)
 
211,447,811
211,511,245
Total Investments Purchased with Cash Collateral from
Securities on Loan
(Cost $293,821,232)
293,813,835
TOTAL INVESTMENTS IN SECURITIES-132.87%
(Cost $1,936,515,005)
1,228,384,022
OTHER ASSETS LESS LIABILITIES-(32.87)%
(303,889,798
)
NET ASSETS-100.00%
$924,494,224
 
See accompanying notes which are an integral part of this schedule.
Invesco Solar ETF (TAN)—(continued)
November 30, 2024
(Unaudited)
Investment Abbreviations:
ADR
-American Depositary Receipt
 
Notes to Schedule of Investments:
(a)
Industry and/or sector classifications used in this report are generally according to the Global Industry Classification Standard, which was developed by and is
the exclusive property and a service mark of MSCI Inc. and Standard & Poor’s.
(b)
All or a portion of this security was out on loan at November 30, 2024.
(c)
Non-income producing security.
(d)
Security purchased or received in a transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The security may be
resold pursuant to an exemption from registration under the 1933 Act, typically to qualified institutional buyers. The aggregate value of these securities at
November 30, 2024 was $50,007,458, which represented 5.41% of the Fund’s Net Assets.
(e)
Affiliated holding. Affiliated holdings are investments in entities which are under common ownership or control of Invesco Ltd. or are investments in entities in
which the Fund owns 5% or more of the outstanding voting securities. The table below shows the Fund’s transactions in, and earnings from, its investments in
affiliates for the three months ended November 30, 2024.
 
 
Value
August 31, 2024
Purchases
at Cost
Proceeds
from Sales
Change in
Unrealized
Appreciation
(Depreciation)
Realized
Gain
Value
November 30, 2024
Dividend
Income
Investments in Affiliated
Money Market Funds:
Invesco Government &
Agency Portfolio,
Institutional Class
$120,097
$15,891,838
$(6,305,003
)
$-
$-
$9,706,932
$12,119
Investments Purchased
with Cash Collateral
from Securities on Loan:
Invesco Private
Government Fund
84,758,203
101,969,423
(104,425,036
)
-
-
82,302,590
992,500
*
Invesco Private Prime
Fund
222,718,484
228,213,056
(239,397,824
)
(26,480
)
4,009
211,511,245
2,683,704
*
Total
$307,596,784
$346,074,317
$(350,127,863
)
$(26,480
)
$4,009
$303,520,767
$3,688,323
 
*
Represents the income earned on the investment of cash collateral. Does not include rebates and fees paid to lending agent or premiums received from
borrowers, if any.
 
(f)
The rate shown is the 7-day SEC standardized yield as of November 30, 2024.
(g)
The security has been segregated to satisfy the commitment to return the cash collateral received in securities lending transactions upon the borrower’s return
of the securities loaned.  
 
This Fund has holdings greater than 10% of net assets in the following country:
 
China
22.92%
The valuation policy and a listing of other significant accounting policies are available in the most recent shareholder report.
See accompanying notes which are an integral part of this schedule.
Notes to Quarterly Schedules of Portfolio Holdings
November 30, 2024
(Unaudited)
NOTE 1—Additional Valuation Information
Generally Accepted Accounting Principles ("GAAP") defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, under current market conditions. GAAP establishes a hierarchy that prioritizes the inputs to valuation methods, giving the highest priority to readily available unadjusted quoted prices in an active market for identical assets (Level 1) and the lowest priority to significant unobservable inputs (Level 3), generally when market prices are not readily available. Based on the valuation inputs, the securities or other investments are tiered into one of three levels. Changes in valuation methods may result in transfers in or out of an investment’s assigned level:
Level 1 — Prices are determined using quoted prices in an active market for identical assets.
Level 2 — Prices are determined using other significant observable inputs. Observable inputs are inputs that other market participants may use in pricing a security. These may include quoted prices for similar securities, interest rates, prepayment speeds, credit risk, yield curves, loss severities, default rates, discount rates, volatilities and others. When significant events cause market movements to occur after the close of the relevant foreign securities markets, foreign securities held by certain Funds may be fair valued utilizing an independent pricing service.
Level 3 — Prices are determined using significant unobservable inputs. In situations where quoted prices or observable inputs are unavailable (for example, when there is little or no market activity for an investment at the end of the period), unobservable inputs may be used. Unobservable inputs reflect Invesco Capital Management LLC’s assumptions about the factors market participants would use in determining fair value of the securities or instruments and would be based on the best available information.
The following is a summary of the tiered valuation input levels, as of November 30, 2024. The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities. Because of the inherent uncertainties of valuation, the values reflected in the financial statements may materially differ from the value received upon actual sale of those investments. 
 
Level 1
Level 2
Level 3
Total
Invesco Nasdaq Biotechnology ETF
Investments in Securities
Common Stocks & Other Equity Interests
$41,046,698
$-
$474
$41,047,172
Money Market Funds
4,110
11,832,195
-
11,836,305
Total Investments
$41,050,808
$11,832,195
$474
$52,883,477
Invesco Nasdaq Free Cash Flow Achievers ETF
Investments in Securities
Common Stocks & Other Equity Interests
$11,031,289
$-
$-
$11,031,289
Money Market Funds
9,419
148,756
-
158,175
Total Investments
$11,040,708
$148,756
$-
$11,189,464
Invesco PHLX Semiconductor ETF
Investments in Securities
Common Stocks & Other Equity Interests
$481,037,322
$-
$-
$481,037,322
Money Market Funds
153,892
17,720,915
-
17,874,807
Total Investments
$481,191,214
$17,720,915
$-
$498,912,129
Invesco Solar ETF
Investments in Securities
Common Stocks & Other Equity Interests
$924,863,255
$-
$-
$924,863,255
Money Market Funds
9,706,932
293,813,835
-
303,520,767
Total Investments
$934,570,187
$293,813,835
$-
$1,228,384,022